MarketPeel
Insider Trading Intelligence
HH

Hans Hull

PLRX
CHIEF BUSINESS OFFICER · PLIANT THERAPEUTICS, INC. · CIK 0001614876
FILING MIX · LIFETIME60%/40%
BUYS
21
SELLS
14
TOTAL VALUE
$2.29M
COMPANIES
1
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
251,708
AVG SELL PX
$17.75
TRADE KIND
SHOWING 35 / 35
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
9 backtested trades · 8 horizons · 2 pending
Forward-return performance of every backtestable P/S trade by Hans Hull, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d9+77.78%-1.44%+0.50%-1.94%-3.04%
14d9+55.56%-3.64%-0.50%-3.15%-4.23%
30d9+55.56%-10.58%+0.83%-11.41%-12.49%
60d9+66.67%-11.42%-0.48%-10.94%-13.23%
90d9+66.67%-20.15%-0.79%-19.36%-18.40%
180d9+55.56%-15.19%+9.96%-25.15%-15.48%
1y9+88.89%-42.49%+22.29%-64.78%-52.10%
2y9(2 pending)+85.71%-83.61%+45.41%-129.03%-134.21%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
PLRX · 251,708 shares · as of Jan 23, 2025
062,927125,854188,781251,70820212022202320242025SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
FLOW · 21 buys / 14 sellsCOVERAGE · 21 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
80,30080,300Jan 23, 2025Jan 27, 2025View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
40,150251,708Jan 23, 2025Jan 27, 2025View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
15,936$11.20$178.5K211,558Jan 17, 2025Jan 22, 2025View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
9,900$11.56$114.4K227,494Jul 10, 2024Jul 12, 2024View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
19,337237,394Jul 9, 2024Jul 11, 2024View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
31,500216,569Jan 23, 2024Jan 24, 2024View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
63,00063,000Jan 23, 2024Jan 24, 2024View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
9,786$17.23$168.6K185,069Jan 17, 2024Jan 19, 2024View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
8,791$2.08$18.3K214,905Aug 4, 2023Aug 7, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
20,050$20.01$401.2K194,855Aug 4, 2023Aug 7, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE
Chief Business Officer
8,79131,367Aug 4, 2023Aug 7, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
1,800$2.08$3.7K207,914Aug 3, 2023Aug 7, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASE10b5-1
10b5-1 plan
1,800$20.00$36.0K206,114Aug 3, 2023Aug 7, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE
Chief Business Officer
1,80040,158Aug 3, 2023Aug 7, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
13,069$20.00$261.4K206,114Aug 3, 2023Aug 7, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
17,937$18.01$323.0K219,183Jul 17, 2023Jul 19, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
35,156237,120Jul 14, 2023Jul 18, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
9,036$26.52$239.6K201,964Mar 30, 2023Apr 3, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
17,578211,000Mar 29, 2023Mar 31, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
76,20076,200Jan 25, 2023Jan 27, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
54,000192,191Jan 25, 2023Jan 27, 2023View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE
Chief Business Officer
8,748$19.10$167.1K138,191Dec 20, 2022Dec 21, 2022View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
17,578146,939Dec 19, 2022Dec 21, 2022View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
112,500112,500Jan 26, 2022Feb 2, 2022View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
4,500$2.08$9.4K125,246May 26, 2021May 28, 2021View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE
Chief Business Officer
4,50012,979May 26, 2021May 28, 2021View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
62,25062,250Jan 23, 2021Jan 26, 2021View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
3,500$2.08$7.3K120,746Dec 30, 2020Jan 4, 2021View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE
Chief Business Officer
3,50017,479Dec 30, 2020Jan 4, 2021View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE
Chief Business Officer
27,3220Jun 5, 2020Jun 9, 2020View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
3,8213,821Jun 5, 2020Jun 9, 2020View →
PLRX
PLIANT THERAPEUTICS, INC.
SALE
Chief Business Officer
36,3190Jun 5, 2020Jun 9, 2020View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASE
Chief Business Officer
5,079117,246Jun 5, 2020Jun 9, 2020View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
70,35270,352Mar 31, 2020Jun 9, 2020View →
PLRX
PLIANT THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
27,322$13.08$357.5K27,322Feb 28, 2020Jun 9, 2020View →
Other insiders · PLRX
Loading peer insiders…
About this filer
CIK 0001614876
ROLE
Chief Business Officer
PRIMARY
PLRX
COMPANIES
1
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001614876DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback